Cargando…
Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects
This double‐blind, randomized, single‐site, crossover trial compared the injection‐site experience with the starting doses of semaglutide and dulaglutide. Healthy subjects (aged 18–75 years; body mass index ≥ 25 kg/m(2); n = 104) were randomized 1:1, using a pregenerated list, to semaglutide 0.25 mg...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251561/ https://www.ncbi.nlm.nih.gov/pubmed/33591618 http://dx.doi.org/10.1111/dom.14349 |
_version_ | 1783717113571049472 |
---|---|
author | Snitker, Søren Andersen, Andreas Berg, Birgitte van Marle, Sjoerd Sparre, Thomas |
author_facet | Snitker, Søren Andersen, Andreas Berg, Birgitte van Marle, Sjoerd Sparre, Thomas |
author_sort | Snitker, Søren |
collection | PubMed |
description | This double‐blind, randomized, single‐site, crossover trial compared the injection‐site experience with the starting doses of semaglutide and dulaglutide. Healthy subjects (aged 18–75 years; body mass index ≥ 25 kg/m(2); n = 104) were randomized 1:1, using a pregenerated list, to semaglutide 0.25 mg as the first injection and dulaglutide 0.75 mg as the second injection or vice versa; each was administered using their proprietary pen‐injectors, according to instructions for use. The primary endpoint was intensity of injection‐site pain, measured using a visual analogue scale (VAS; 0 mm = no pain, 100 mm = unbearable pain). Exploratory endpoints included intensity category, duration and quality of injection‐site pain, and comparative assessment of injection‐site pain with the two injections. The point estimate of the VAS score for injection‐site pain intensity was 11.5 mm with dulaglutide versus 5.6 mm with semaglutide; mean (95% confidence interval) estimated treatment difference 5.9 (3.6; 8.2) mm; p < .0001. Other endpoints corroborated a less painful injection experience with semaglutide versus dulaglutide. Safety was consistent with reported data for the drugs. In conclusion, the injection‐site experience with semaglutide was rated as less painful than that with dulaglutide. |
format | Online Article Text |
id | pubmed-8251561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-82515612021-07-06 Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects Snitker, Søren Andersen, Andreas Berg, Birgitte van Marle, Sjoerd Sparre, Thomas Diabetes Obes Metab Brief Reports This double‐blind, randomized, single‐site, crossover trial compared the injection‐site experience with the starting doses of semaglutide and dulaglutide. Healthy subjects (aged 18–75 years; body mass index ≥ 25 kg/m(2); n = 104) were randomized 1:1, using a pregenerated list, to semaglutide 0.25 mg as the first injection and dulaglutide 0.75 mg as the second injection or vice versa; each was administered using their proprietary pen‐injectors, according to instructions for use. The primary endpoint was intensity of injection‐site pain, measured using a visual analogue scale (VAS; 0 mm = no pain, 100 mm = unbearable pain). Exploratory endpoints included intensity category, duration and quality of injection‐site pain, and comparative assessment of injection‐site pain with the two injections. The point estimate of the VAS score for injection‐site pain intensity was 11.5 mm with dulaglutide versus 5.6 mm with semaglutide; mean (95% confidence interval) estimated treatment difference 5.9 (3.6; 8.2) mm; p < .0001. Other endpoints corroborated a less painful injection experience with semaglutide versus dulaglutide. Safety was consistent with reported data for the drugs. In conclusion, the injection‐site experience with semaglutide was rated as less painful than that with dulaglutide. Blackwell Publishing Ltd 2021-03-18 2021-06 /pmc/articles/PMC8251561/ /pubmed/33591618 http://dx.doi.org/10.1111/dom.14349 Text en © 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Brief Reports Snitker, Søren Andersen, Andreas Berg, Birgitte van Marle, Sjoerd Sparre, Thomas Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects |
title | Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects |
title_full | Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects |
title_fullStr | Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects |
title_full_unstemmed | Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects |
title_short | Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects |
title_sort | comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: a randomized, double‐blind trial in healthy subjects |
topic | Brief Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251561/ https://www.ncbi.nlm.nih.gov/pubmed/33591618 http://dx.doi.org/10.1111/dom.14349 |
work_keys_str_mv | AT snitkersøren comparisonoftheinjectionsiteexperienceofthestartingdoseswithsemaglutideanddulaglutidearandomizeddoubleblindtrialinhealthysubjects AT andersenandreas comparisonoftheinjectionsiteexperienceofthestartingdoseswithsemaglutideanddulaglutidearandomizeddoubleblindtrialinhealthysubjects AT bergbirgitte comparisonoftheinjectionsiteexperienceofthestartingdoseswithsemaglutideanddulaglutidearandomizeddoubleblindtrialinhealthysubjects AT vanmarlesjoerd comparisonoftheinjectionsiteexperienceofthestartingdoseswithsemaglutideanddulaglutidearandomizeddoubleblindtrialinhealthysubjects AT sparrethomas comparisonoftheinjectionsiteexperienceofthestartingdoseswithsemaglutideanddulaglutidearandomizeddoubleblindtrialinhealthysubjects |